-
-
-
-
-
-
-
Summit's ivonescimab shows survival benefit in lung cancer trial
-
-
-
-
-
-
-
Summit Therapeutics (SMMT) Tops Q1 EPS by 4c
-
-
-
-
-
-
-
Summit Therapeutics (SMMT) Added to Citi 90-Day Upside Catalyst Call List
-
-
-
-
-
-
-
Summit Therapeutics (SMMT) Reiterated at Market Outperform by Citizens
-
-
-
-
-
-
-
Barclays Upgrades Summit Therapeutics plc (SMMT) to Equalweight
-
-
-
-
-
-
-
UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
-
-
-
-
-
-
-
Citi Opens 30-Day Upside Catalyst Watch on Summit Therapeutics plc (SMMT)
-
427,903 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

